Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis (Details)

v3.26.1
Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Assets:    
Exarafenib milestone asset $ 3,704 $ 3,600
Castle Creek warrants 709 697
Liabilities:    
Exarafenib milestone contingent consideration 3,704 3,600
Share-based liability   3,197
Significant Unobservable Inputs (Level 3)    
Liabilities:    
Share-based liability 0 3,200
Fair Value, Recurring    
Assets:    
Cash equivalents 75,340 48,140
Exarafenib milestone asset 3,704 3,600
Investment in equity securities 494 382
Castle Creek warrants 709 697
Total financial assets 80,247 52,819
Liabilities:    
Exarafenib milestone contingent consideration 3,704 3,600
Share-based liability   3,197
Total financial liabilities 3,704 6,797
Fair Value, Recurring | Money market funds    
Assets:    
Cash equivalents 49,835 41,810
Fair Value, Recurring | U.S. treasury bills    
Assets:    
Cash equivalents 25,505 6,330
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Cash equivalents 75,340 48,140
Investment in equity securities 494 382
Total financial assets 75,834 48,522
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Assets:    
Cash equivalents 49,835 41,810
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. treasury bills    
Assets:    
Cash equivalents 25,505 6,330
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Assets:    
Exarafenib milestone asset 3,704 3,600
Castle Creek warrants 709 697
Total financial assets 4,413 4,297
Liabilities:    
Exarafenib milestone contingent consideration 3,704 3,600
Share-based liability   3,197
Total financial liabilities $ 3,704 $ 6,797